HeartSciences reports no FQ3 2026 revenue, cash at $3.4M; MyoVista platform advances

HeartSciences Inc.

No revenue for FQ3 2026; cash and equivalents $3.4M, shareholders' equity $2.7M as of Jan 31.
MyoVista Insights platform got major upgrade March 13; deploying across health systems.
MyoVista wavECG device submitted to FDA for 510(k) clearance in Dec 2025.
Company expects key customer wins and initial revenues during 2026.
Management to host investor call after ACC meeting to demo platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HeartSciences Inc. reported fiscal third quarter ended January 31, 2026 results: revenue no meaningful revenue.

Period: fiscal third quarter ended January 31, 2026
Revenue: no meaningful revenue
Result: reported results

Exact text from the filing

HeartSciences reported no meaningful revenue for FQ3 2026

View on SEC.gov

Browse all earnings releases →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-008420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.